Hiba Graham

Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial

Therapeutic strategies for COVID-19: progress and lessons learned

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial

Cobicistat-Boosted Protease Inhibitors in HIV-Infected Patients with Mild to Moderate Renal Impairment